Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Trial end date:
Target enrollment:
Participant gender:
The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management. Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.
Phase 1
Accepts Healthy Volunteers?
Lead Sponsor:
Jesse Corry
Inclusion Criteria:

1. Age >18 years old and < 80 years.

2. Diagnosis of primary ICH > 20 cc in volume.

3. Enrollment within 48 hours from initial symptoms.

4. Signed informed consent from the patient or obtained via their legally authorized
representative (if the patient is not able to sign the informed consent themselves).
The patient's decisional capacity to either provide or refuse consent will be
determined using the Glasgow Coma Scale (GCS), which is being assessed at baseline and
at 24 hours (+/-6hrs) after enrollment. A potential study participant with a GCS > 14
will be asked to provide their own initial study consent. A GCS ≤ 14 would indicate
the need to pursue consent via legally authorized representative.

Exclusion Criteria:

1. Current need for renal replacement therapy (RRT).

2. Glomerular filtration rate (GFR) of <30 mL/minute at time of admission.

3. Participation in another study for ICH or intraventricular hemorrhage.

4. ICH related to infection, thrombolysis, subarachnoid hemorrhage, trauma or tumor.

5. Presence of HIV or active fungal infection that is known based on information in the
electronic medical record (EMR).

6. Continued use of digoxin or amlodipine (as recommended by the manufacturer due to
cytochrome P450 3A4 "CYP3A" inhibition).

7. Active hepatic failure as defined by aspartate aminotransferase (AST) >160 units/L
and/or alanine transaminase (ALT) >180 units/L, or total bilirubin levels greater than
four times normal levels (>4.8mg/dL).

8. Serum Na+> 145 mmol/L (admission labs or any time prior to recruitment/enrollment).

9. Unable to receive conivaptan based on contraindications indicated by the manufacturer.

10. Pregnant or lactating females.

11. Not expected to survive within 48 hours of admission, or a presumed diagnosis of brain